Bexion Pharmaceuticals has launched part 3 of its phase 1 clinical trial for BXQ-350, an investigational cancer treatment aimed at advancing the fight against solid tumors. This milestone marks a significant step forward for the US-based pharma company, which has been diligently working to explore the therapeutic potential of BXQ-350. The phase 1 trial, still […]
US-based biotech company X-Rx has received a major boost in its quest to develop new treatments for Idiopathic Pulmonary Fibrosis (IPF) with the US Food and Drug Administration (FDA) accepting its Investigational New Drug (IND) application for X-165, an innovative small molecule inhibitor of Autotaxin. This approval opens the door to clinical trials for X-165, […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]